Management of hepatitis B virus reactivation due to treatment of COVID-19
코로나19 치료로 인한 B형 간염 바이러스 재활성화 관리
Review
[키워드] Antiviral
Baricitinib
Corticosteroids
COVID-19
COVID-19 infection
COVID-19 patient
COVID-19 patients
current
dysregulated
Evidence
Future
HBV
HBV infection
Hepatitis
hepatitis B
Hepatitis B virus
High-dose
Immunosuppression
immunosuppressive
immunosuppressive therapies
immunosuppressive therapy
increased risk
Infection
Inflammatory response
inhibitor
inhibitors
janus
Janus kinase
Liver function test
Liver injury
management
monoclonal antibody
other diseases
pandemic
Patient
potentially life-threatening
Prophylaxis
Reactivation
receiving
risk
sarilumab
SARS-CoV-2
severe disease
the patient
Therapies
Tocilizumab
Tofacitinib
Treatment
treatments for COVID-19
treatments of COVID-19
[DOI] 10.1007/s12072-022-10306-x PMC 바로가기 [Article Type] Review
[DOI] 10.1007/s12072-022-10306-x PMC 바로가기 [Article Type] Review